Bank of America upgraded Kimberly-Clark to a 'Buy' rating with a $120 price target following its acquisition of Kenvue assets. The deal, valued at about 14 times Kenvue's adjusted EBITDA, could generate $32 billion in combined revenue and $7 billion in EBITDA. Despite skepticism over cost and revenue synergy targets, analysts see potential value creation, especially if sector valuations improve. Kimberly-Clark's acquisition complements its product range, with strong brands like Tylenol and Zyrtec highlighted, while litigation concerns are easing.
Kimberly-Clark Corporation announced a quarterly dividend of $1.28 per share, payable July 2, 2026, to shareholders recorded by June 5, 2026. This marks the company's 92nd consecutive year of paying dividends and 54th year of increasing them, undersc...
High-yield dividend stocks are rare in the current market, but five companies, including Verizon Communications, Best Buy, Kimberly-Clark, and two others, offer dividend yields above 5% while also growing their earnings. These companies beat earnings...
